CareDx, Inc (NASDAQ:CDNA) Holdings Lowered by Russell Investments Group Ltd.

Russell Investments Group Ltd. reduced its position in CareDx, Inc (NASDAQ:CDNA - Free Report) by 41.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 313,259 shares of the company's stock after selling 222,114 shares during the quarter. Russell Investments Group Ltd. owned about 0.58% of CareDx worth $6,707,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Plato Investment Management Ltd raised its holdings in shares of CareDx by 34.1% in the 4th quarter. Plato Investment Management Ltd now owns 5,390 shares of the company's stock worth $116,000 after purchasing an additional 1,370 shares during the period. IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its position in CareDx by 41.5% during the fourth quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 9,343 shares of the company's stock valued at $200,000 after buying an additional 2,742 shares in the last quarter. KLP Kapitalforvaltning AS purchased a new stake in CareDx during the fourth quarter worth approximately $208,000. Cornercap Investment Counsel Inc. purchased a new stake in CareDx during the fourth quarter worth approximately $214,000. Finally, Inceptionr LLC acquired a new stake in shares of CareDx in the fourth quarter worth $240,000.

Analyst Ratings Changes

A number of brokerages recently weighed in on CDNA. Stephens reaffirmed an "overweight" rating and set a $40.00 price target on shares of CareDx in a research report on Thursday, February 27th. StockNews.com raised shares of CareDx from a "hold" rating to a "buy" rating in a research report on Wednesday, February 26th. Wells Fargo & Company raised shares of CareDx from an "underweight" rating to an "equal weight" rating and reduced their target price for the stock from $28.00 to $24.00 in a research report on Wednesday, January 15th. Finally, HC Wainwright decreased their price objective on shares of CareDx from $26.00 to $25.00 and set a "neutral" rating for the company in a research report on Monday, March 3rd. Three analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $31.83.

Remove Ads

CareDx Stock Down 4.9 %

CDNA stock traded down $0.94 during midday trading on Wednesday, reaching $18.22. The company had a trading volume of 507,044 shares, compared to its average volume of 855,831. The firm has a market capitalization of $1.01 billion, a PE ratio of -6.75 and a beta of 2.18. The stock has a 50 day moving average price of $20.06 and a 200 day moving average price of $22.59. CareDx, Inc has a fifty-two week low of $7.42 and a fifty-two week high of $34.84.

CareDx (NASDAQ:CDNA - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The company reported $1.51 EPS for the quarter, topping analysts' consensus estimates of $0.05 by $1.46. The firm had revenue of $86.58 million during the quarter, compared to the consensus estimate of $84.56 million. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. Research analysts predict that CareDx, Inc will post -0.9 EPS for the current year.

About CareDx

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.